Navigation Links
ARIUS announces second quarter fiscal 2008 financial results
Date:7/11/2008

TORONTO, July 11 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX: ARI), a biotechnology company discovering and developing the next wave of antibody therapeutics, today announced its financial and operational results for the second fiscal quarter of 2008, ended May 31st, 2008.

"Throughout the second quarter, we maintained our focus on moving ARIUS' anti-cancer antibodies towards human clinical trial. Most notably, our lead drug candidates received significant attention from the scientific community this quarter as five abstracts were presented at the AACR Annual Meeting in April, disclosing new findings about our CD44, Trop-2, CD59, and CD9 antibody programs," said Dr. David Young, President and CEO of ARIUS. "Additionally, abstracts on our CD44 program were selected for publication at the ASCO Annual Meeting in May. The inclusion of ARIUS' findings at these important conferences demonstrates the high quality of our research and reinforces the value of our lead drug candidates."

Program Updates:

CD44 Cancer Stem Cell Program

- Presented two CD44-focused posters at AACR the American Association

for Cancer Research (AACR) Annual Meeting held from April 12-16, 2008

in San Diego, California.

- Published two CD44-focused abstracts at the American Association for

Clinical Oncology (ASCO) Annual Meeting held from May 30-June 3, 2008

in Chicago, Illinois.

- Held meeting with FDA to discuss plans for the upcoming IND

submission in the first quarter of 2008.

- ARIUS plans to have clinical trials' materials prepared in the fourth

quarter of 2008 and then a Phase I IND application is expected to be

filed and human clinical trials commenced.

Trop-2 Signal Transduction Program

- Completed two toxicology studies with no dose-limiting toxicity.

- Presented a Trop-2-focused poster at AACR Annual Meeting.

- Engaged
'/>"/>

SOURCE ARIUS Research Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. ARIUS presents new findings for anti-cancer antibody programs at AACR
2. ARIUS announces first quarter fiscal 2008 financial results
3. ARIUS 2008 Annual and Special Meeting of Shareholders
4. ARIUS recognized for entrepreneurial excellence
5. ARIUS announces five abstracts selected for presentation at 2008 AACR Annual Meeting
6. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
7. Laureate Announces Manufacturing Agreement with ARIUS for Trop-2 Targeting Antibody
8. ARIUS announces manufacturing Agreement with Laureate Pharma For Trop-2 targeting antibody
9. ARIUS announces fourth quarter and year-end fiscal 2007 financial results
10. Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program
11. ARIUS to Hold Fourth Quarter and Year End 2007 Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... EntreMed, Inc. (Nasdaq: ENMD ), ... royalty revenue from sales of Thalomid® during the ... $3.3 million. In addition, the Company anticipates ... for fiscal 2009. The difference in estimated ... be reflected in the fourth quarter financial results. ...
(Date:12/11/2009)... December 10, 2009 miRagen Therapeutics, Inc., a ... developing innovative microRNA-based therapeutics for cardiovascular and muscle ... that microRNA-206 (miR-206) plays a crucial role in ... Lou Gehrig,s disease) and in neuromuscular synaptic regeneration ... December 11 issue of the journal Science ...
(Date:12/11/2009)... HILL, MA (12/11/2009) Boston College researchers have observed ... the first time and successfully harvested the elusive charges ... improved solar power efficiency, the authors report in the ... , When light is captured in solar cells, it ... But in order to snare these charges, the electrons ...
(Date:12/11/2009)... Algeta ASA (OSE: ALGETA), the,cancer ... center in the,US, the Tulane Cancer Center, ... phase III clinical study of Alpharadin in ... cancer,(CRPC) that has metastasized to the skeleton. ... (ALpharadin in SYMptomatic Prostate CAncer) study is ...
Breaking Biology Technology:EntreMed Reports Receipt of Third Quarter Royalty Payment 2miRagen announces discovery of key microRNA implicated in Lou Gehrig's disease 2Elusive 'hot' electrons captured in ultra-thin solar cells 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 2Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 3Algeta Announces First US Patient Randomized in ALSYMPCA Phase III Study at Tulane Cancer Center, New Orleans 4
... Arno Therapeutics, Inc., a,privately held drug development company, ... agreements with The Ohio State University,("OSU") for the ... for cancer., Pursuant to the license agreements, ... the treatment of cancer, including OSU-03012 (NSC,D728209) and ...
... Continued Development of CNDO103 as ... Cancer ... the publication of data demonstrating that the Bcl-2 inhibitor,Apogossypol, effectively killed ... Gossypol in vivo in mice., Published online in Blood (Jan. ...
... 28 /PRNewswire-FirstCall/ - ARIUS Research Inc., (TSX:,ARI), a ... of,antibody therapeutics, today announced it has completed its ... discuss the upcoming IND,submission for ARH460-16-2, its lead ... antibody targeting a novel epitope of CD44,found in ...
Other Biology Technology:Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 2Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds 3Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 2Study Shows Coronado Biosciences' Bcl-2 Inhibitor, Apogossypol, is More Efficacious, Less Toxic than Gossypol in Animal Models 3Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 2Arius completes Pre-IND Meeting with FDA for Lead CD44 Cancer Stem Cell Program 3
(Date:12/14/2009)... A team of researchers from the Astrobiology Centre (INTA-CSIC) ... considered essential to the formation of the most basic ... blue. In order to carry out this study, published ... scientists recreated the chemical conditions of the early Earth. ... dissolved in ammoniac solutions it produces hydrogen cyanide, a ...
(Date:12/14/2009)... WAYNE, Pa., Dec. 14 MODA Technology ... monitoring (EM), utility and product testing for the ... MODA 3.0, the company,s third generation mobile data ... (QC) organizations to further automate their regulated manufacturing ... new capabilities: ,, Fully-Configurable Test Methods: ...
(Date:12/13/2009)... about how a popular class of drugs used ... previously hidden components of chemical communication in the ... the illness, people with schizophrenia also struggle to ... order, difficulties that interfere with their ability to ... Schroeder, a student in the medical scientist training ...
Breaking Biology News(10 mins):Prussian blue linked to the origin of life 2MODA Announces Availability of Third Generation Mobile Data Acquisition Platform 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2ARKRAY Inc Receives FDA Clearance for New GLUCOCARD 28R 29 Vital 28TM 29 Blood Glucose Monitoring System 6035 1ARKRAY Inc Receives FDA Clearance for New GLUCOCARD 28R 29 Vital 28TM 29 Blood Glucose Monitoring System 6035 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 1Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 2Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 3Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 4Cardiac Science Appoints Healthcare Executive Ronald A Andrews Jr to Board of Directors 6032 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 1Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 2Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 3Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 4Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 5Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 6Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 7Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 8Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 9Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 10Genoptix Reports Continued Strong Growth for the Third Quarter and First Nine Months of 2009 6029 11
... The Stowers Institute,s Rong Li Lab has published findings that ... disruptions to their basic division machineries findings that may ... mechanisms or chemotherapy treatment. The work was published in the ... with yeast cells, the team disabled a motor protein, type ...
... The United States has been under assault for decades ... it is not often that one of these aliens faces ... institutions, the University of Rhode Island has scored a knockout., ... trees, has been virtually eradicated in the Northeast. And ...
... one of the oldest diseases known to man, has ... More than 1 million children die from malaria in ... Thailand/Cambodian border multiple drug-resistant strains of the disease are ... nearly ineffective due to drug resistance and traditional public ...
Other Biology News:Rong Li Lab offers insight into adaptive ability of cells 2URI researchers help score knockout punch on birch tree pest 2
... the caudal-related homeobox family, is an intestine-specific ... differentiation in intestinal epithelial cells. It plays ... the phenotype of differentiated villus enterocytes as ... phenotype. Clone CDX2-88 reacts with a conserved ...
Rabbit polyclonal to VPAC2 ( Abpromise for all tested applications). entrezGeneID: 7434 SwissProtID: P41587...
Mouse Anti-Human Methyl-CpG binding domain protein 2 (MBD2 Monoclonal Antibody Family: Other Applications: Western Blot...
... and rocking for maximal fluid movement. This unit ... steel or acrylic platform, it is perfect for ... platform angle is easily adjusted from 0 to ... rotation speed of platform is adjusted from 0 ...
Biology Products: